Literature DB >> 8608237

CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas.

J F Emile1, M L Boulland, C Haioun, P Kanavaros, T Petrella, M H Delfau-Larue, A Bensussan, J P Farcet, P Gaulard.   

Abstract

Non-Hodgkin's lymphomas are divided into B- and T-cell neoplasms. The existence and the clinical relevance of lymphomas derived from the third lymphocyte lineage, ie, natural killer (NK) cells are still controversial. NK cells are lymphocytes that mediate cytotoxicity without prior sensitization. NK cells also have phenotypic and genotypic characteristics: they express the NK-related antigen CD56, T-cell markers such as CD2 and CD7, but do not express CD5 and T-cell receptor (TCR) proteins, and their TCR locus is not rearranged. Therefore, if NK cell lymphomas exist, they should express some T-cell markers, but not alpha beta or gamma delta TCR proteins. Such lymphomas are actually called TCR silent peripheral T cell lymphomas (PTCL). To detect and characterize NK cell lymphomas, we investigated the immunophenotype and immunogenotype of 35 patients with TCR silent PTCL. The first group included 16 patients with a lymphoma of CD5-CD56+ phenotype, which is identical to normal NK cells. These patients had either a nasal/nasopharyngeal lymphoma (11 cases) or a lymphoma with predominant non-nasal/non-nodal initial involvement (five cases). Eight of the nine cases for which immunogenotypic data were available lacked clonal rearrangement of the TCR gamma genes. Thus, these tumors are likely to be NK cell lymphomas. The second group of 15 cases had a CD5+ phenotype (14 were CD56-, and 1 was CD56+) and clonal rearrangement of TCR gamma genes, indicating that they were true PTCL with unproductive TCR rearrangement. The four remaining cases were CD5- CD56- lymphomas and disclosed either a clonal (two cases) or no clonal (two cases) rearrangements of the TCR gamma genes. Altogether these findings show that CD5-CD56+ so-called "TCR silent PTCL" bear the immunophenotype and immunogenotype of normal NK cells and display peculiar clinical features distinct from true PTCL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608237

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.

Authors:  E Berti; D Tomasini; M H Vermeer; C J Meijer; E Alessi; R Willemze
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature.

Authors:  John Ryder; Xiaoqin Wang; Liming Bao; Sherilyn A Gross; Fu Hua; Richard D Irons
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

3.  CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer.

Authors:  Chalid Assaf; Sylke Gellrich; Sean Whittaker; Alistair Robson; Lorenzo Cerroni; Cesare Massone; Helmut Kerl; Christian Rose; Andreas Chott; Sergio Chimenti; Christian Hallermann; Tony Petrella; Janine Wechsler; Martine Bagot; Michael Hummel; Katrin Bullani-Kerl; Marcel W Bekkenk; Werner Kempf; Chris J L M Meijer; Rein Willemze; Wolfram Sterry
Journal:  J Clin Pathol       Date:  2006-10-03       Impact factor: 3.411

4.  TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation.

Authors:  R E Felgar; W R Macon; M C Kinney; S Roberts; T Pasha; K E Salhany
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

5.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

6.  Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior.

Authors:  Mineui Hong; Taehee Lee; So Young Kang; Suk-Jin Kim; Wonseog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

Review 7.  NK cell lymphoma.

Authors:  Kazuo Oshimi
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Authors:  Takumi Kumai; Toshihiro Nagato; Hiroya Kobayashi; Yuki Komabayashi; Seigo Ueda; Kan Kishibe; Takayuki Ohkuri; Miki Takahara; Esteban Celis; Yasuaki Harabuchi
Journal:  Cancer Immunol Immunother       Date:  2015-03-10       Impact factor: 6.968

9.  Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas.

Authors:  M L Boulland; V Meignin; K Leroy-Viard; C Copie-Bergman; J Brière; R Touitou; P Kanavaros; P Gaulard
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

Review 10.  Leukemia and lymphoma of natural killer lineage cells.

Authors:  Kazuo Oshimi
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.